Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

View/Open

Supporting information (63.31Kb)

Date

2017-10

ICR Author

Marsden,

Author

Seddon, B

Strauss, SJ

Whelan, J

Leahy, M

Woll, PJ

Cowie, F

Rothermundt, C

Wood, Z

Benson, C

Ali, N

Marples, M

Veal, GJ

Jamieson, D

Küver, K

Tirabosco, R

Forsyth, S

Nash, S

Dehbi, H-M

Beare, S

Show allShow less

Type

Journal Article

Metadata

Show full item record

URI

https://repository.icr.ac.uk/handle/internal/1450

DOI

https://doi.org/10.1016/s1470-2045(17)30622-8

Collections

• Other ICR Research

Language

eng

License start date

2017-10

Citation

The Lancet Oncology, 2017, 18 (10), pp. 1397 - 1410

Publisher

Elsevier BV